Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. - Wikidata - wikimedia - TriplyDB

Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis.

Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis.

http://www.wikidata.org/entity/Q36370513

about

Recent developments in esophageal adenocarcinoma Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease Barrett's oesophagus: frequency and prediction of dysplasia and cancer NSAIDs modulate clonal evolution in Barrett's esophagus.NSAIDs Use and Reduced Metastasis in Cancer Patients: results from a meta-analysis Risk factors for the development of oesophageal adenocarcinoma in Barrett's oesophagus: a UK primary care retrospective nested case-control study.Physical activity is associated with reduced risk of esophageal cancer, particularly esophageal adenocarcinoma: a systematic review and meta-analysis.Risk of esophageal adenocarcinoma decreases with height, based on consortium analysis and confirmed by Mendelian randomization.Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis.Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis Questionnaire-based survey conducted in 2011 concerning endoscopic management of Barrett's esophagus in East Asian countries.British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus.Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett's esophagus cohort.Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagus.NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.Precision prevention of oesophageal adenocarcinoma.Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy.Acid-suppressive Medications and Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus(Gut 2014;63:1229-1237).Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma Current status and future perspectives on the etiology of esophageal adenocarcinoma.Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.Age-specific risk factor profiles of adenocarcinomas of the esophagus: A pooled analysis from the international BEACON consortium.Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma.Prediagnosis aspirin use and outcomes in a prospective cohort of esophageal cancer patients.Risk stratification for malignant progression in Barrett's esophagus: Gender, age, duration and year of surveillance Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus.Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett's esophagus.The frequency of histologically confirmed Barrett's esophagus varies by the combination of ethnicity and gender.Barrett's esophagus: best practices for treatment and post-treatment surveillance.Management strategies of Barrett's esophagus A review of the epidemiology of Barrett's oesophagus and oesophageal adenocarcinoma.Carcinogenesis of Barrett's esophagus: a review of the clinical literature.Barrett's oesophagus: how should we manage it?Barrett's esophagus: diagnosis and management.Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma.The non-linear threshold association between aspirin use and esophageal adenocarcinoma: results of a dose-response meta-analysis.Live imaging of tumor initiation in zebrafish larvae reveals a trophic role for leukocyte-derived PGE₂.Esophageal COX-2 expression is increased in Barrett's esophagus, obesity, and smoking.Aspirin prevents NF-κB activation and CDX2 expression stimulated by acid and bile salts in oesophageal squamous cells of patients with Barrett's oesophagus.

P2860

Q26849652-A9F643C5-9701-414E-9DF5-78A1E015C4C6 Q27027061-4E8EC059-B1D4-4BF1-9B1D-D32B87E13E5A Q28080794-347F0516-5D7C-4482-AD5A-ECE44D7647FA Q31119674-2C838A91-366E-4F14-A473-9D6DD8971846 Q33687606-10009A00-CFE0-47EB-A4A7-82B2C63014F7 Q33695661-68E4F8E0-0544-442C-8A49-89272C4A6790 Q33756930-8526C03A-715D-4923-996D-D62798ED88F8 Q34036491-A9789540-61B1-4026-ADEC-D1DB7A3D240D Q34324864-074C9255-A7D0-4ECA-A0A3-2B2FE71AE035 Q34352867-10C5A26B-7DAE-4A6F-A4D5-1214AACEDC96 Q34356804-70819AD7-E924-4292-B6E3-095DBB7155A1 Q34380645-71FB64B0-C0E9-4319-BE37-66134A3679BA Q34457732-B15DD3B7-A299-41EB-AC35-2D1E9AB56603 Q35007536-D321895B-7FA7-4940-90D7-80427B2226E1 Q35046884-74E415BC-BEE7-4A8A-BDCC-1477A40E98FF Q35243217-861D8807-0655-40DB-BAF8-52F7CA1DF79C Q35251869-E0E112B3-4BBA-48C8-9344-616D90C5629C Q35430468-1C4CF595-D947-4AE0-8A4D-D139208A9EE0 Q35666515-DAD03B27-FF61-4D87-8E66-FEB4E64F5E7F Q35893814-45E82E8A-4EA3-4568-BB4F-22F40A60F186 Q35972032-C43F9F79-3022-48B2-A1D9-8C07816DB7FF Q36076749-DD71E5B3-C1A3-4943-8B33-058CE2DABAAF Q36167133-13A2A76F-FDB7-41E7-8954-5F7692908DC5 Q36444733-A0B26336-02A6-4A48-AFEE-F96F81B255FD Q37361447-D2D58C5D-C2D9-40F1-BEA2-951BCF52EAB9 Q37538933-CB5960F6-6FDB-4861-BECE-ADE671BC3EB5 Q37554702-20EB80A1-726F-46EC-A0FD-283FDBD78073 Q37621036-64D599C7-C2EE-4100-8BF6-C95230680CAD Q37677518-EF510069-AB88-45EF-BEC9-B865125CEABC Q37747384-77A8D94E-FC41-45B7-90C3-E149B23357ED Q38062526-5F018CAF-D5D9-4F80-A663-1DAE9834D7DB Q38368081-F8B0A482-7812-456F-B638-7F5A37AD2B1C Q38548565-659A4E11-04A1-4EF6-8767-7CE245358A09 Q38608994-216F37CD-9569-45F6-BBC7-CCF736112CD5 Q39097596-8C2C02C9-6053-4250-BFFD-3DB811FC50E7 Q39530717-808E16AF-05AB-4609-B132-A67A4AA2A7D1 Q39607611-6BE564F8-EBF6-4C7D-9EBB-E24F9C636000 Q42239372-840852A0-5AB0-4C49-AD8D-CDDFF019DA2C Q46044763-34B620EC-A788-4FC4-A99E-89AA34C4DCDA Q48233200-67929EE2-D000-4A71-9358-C00B46B61A15

P2860

Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis.

http://www.wikidata.org/entity/Q36370513

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Nonsteroidal anti-inflammatory ...... junction in a pooled analysis.

@ast

Nonsteroidal anti-inflammatory ...... junction in a pooled analysis.

@en

type

label

Nonsteroidal anti-inflammatory ...... junction in a pooled analysis.

@ast

Nonsteroidal anti-inflammatory ...... junction in a pooled analysis.

@en

prefLabel

Nonsteroidal anti-inflammatory ...... junction in a pooled analysis.

@ast

Nonsteroidal anti-inflammatory ...... junction in a pooled analysis.

@en

P1433

Q36370513-229E63B0-632B-4758-A3BE-7115F16D4C48

P1476

Q36370513-7C27F883-CE21-4BA9-9AF8-0FC363CD8580

P2093

Q36370513-1E69D812-B61E-4F34-B4AF-F467176B3A3C

Q36370513-24F9D4C9-A359-4BA9-A240-48B575C003E5

Q36370513-35FD3996-9000-47EE-A792-DF32A5752504

Q36370513-537B1386-F00E-4EC9-A5A0-62C37D3E5922

Q36370513-5882E2F6-0D08-4334-8F3C-B8D8D709B886

Q36370513-608AB08A-B2EF-4253-AB66-344E3A96433A

Q36370513-841A998B-4477-4324-81C2-1BC74F64A81D

Q36370513-9A54667C-01E1-4348-8CC1-4EBC079BD7D0

Q36370513-C3CD454B-B89A-4C46-88EA-A15D2C19DD9B

Q36370513-D0BD9AE5-8841-48A4-B320-1E0B17473EA8

P2860

Q36370513-0536E9F6-5E94-4E59-B417-C866DCCCBE19

Q36370513-067B1E24-38AA-442F-944B-EDDB83D567F6

Q36370513-15806F20-DCF1-428D-85E6-F798B6FF8E4C

Q36370513-1DF07BDB-0CD2-4E03-8806-36CAE5A15375

Q36370513-1E10AB65-C07C-4EF1-8C37-8C7EAEAEBD18

Q36370513-1E49963F-96BA-4C9D-9743-D55B25FF81E2

Q36370513-2231835F-A149-46FB-981F-9BF07C2399D5

Q36370513-24B2EA7A-9D4D-43F1-ABD8-D8B35B0F1EBE

Q36370513-2ED33B7B-9A82-4F16-8809-641CE0EF8635

Q36370513-30716BEE-0A25-4DB3-AB93-65DC3359D10E

P304

Q36370513-6873DBF0-7459-4708-B255-58D6DDF30FFB

P31

Q36370513-37a203f8-b448-4f09-96eb-672124de1506

Q36370513-67755C1D-42D5-4B7B-AA29-9ADD5289B0B8

P356

Q36370513-CA9316DD-5566-4191-B37E-9EF6E8C9EB3E

P407

Q36370513-73AECEBB-DFB4-4EA6-A263-E173AAA91990

P433

Q36370513-8046895D-1FF2-4421-8848-BE78C9B8F587

P478

Q36370513-4D1193E1-1792-4527-804A-4CAE62709EE8

P50

Q36370513-00B5D505-7C52-441B-BA71-2797A99631BA

Q36370513-159A3B39-B3B3-4E9C-AAE8-A61F663175A7

Q36370513-7AD57C9D-1A20-4285-94C6-C87E903819DE

Q36370513-AF7A4789-7020-49A6-AEB6-70A866CAA454

Q36370513-C78B9ABF-C07B-4B5E-81B9-139FA4A49362

P577

Q36370513-913EB93E-6725-4AF5-8E56-B40D70BB0604

P5875

Q36370513-BEDCC301-9F84-4437-AA3D-724027535C81

P698

Q36370513-865B1026-9F3B-4213-8D8E-9140883CA049

P921

Q36370513-B388D5C9-62AC-4034-9F7E-394FAABAA77B

Q36370513-C1543872-E43A-4AC8-93AD-0AB3F5D523F0

P932

Q36370513-6677A208-D860-4287-95E4-1ED0DCDA47A5

P356

J.GASTRO.2011.11.019

P1433

Gastroenterology

P1476

Nonsteroidal anti-inflammatory ...... junction in a pooled analysis.

@en

P2093

Alan G Casson

http://www.w3.org/2001/XMLSchema#string

Anna H Wu

http://www.w3.org/2001/XMLSchema#string

Carol Giffen

http://www.w3.org/2001/XMLSchema#string

Douglas A Corley

http://www.w3.org/2001/XMLSchema#string

Farin Kamangar

http://www.w3.org/2001/XMLSchema#string

Harvey A Risch

http://www.w3.org/2001/XMLSchema#string

Liam J Murray

http://www.w3.org/2001/XMLSchema#string

Marilie D Gammon

http://www.w3.org/2001/XMLSchema#string

Michael B Cook

http://www.w3.org/2001/XMLSchema#string

Neal D Freedman

http://www.w3.org/2001/XMLSchema#string

P2860

Measuring inconsistency in meta-analyses

Cyclooxygenase-2 inhibition and gastric cancer

Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis

Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study

Aspirin and risk for gastric cancer: a population-based case-control study in Sweden

Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence

Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues

NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action

Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis

Chemoprevention in gastrointestinal cancers: current status

P304

442-452.e5; quiz e22-3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2011.11.019

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

142

http://www.w3.org/2001/XMLSchema#string

P50

Christian C. Abnet

David C. Whiteman

Nirmala Pandeya

Leslie Bernstein

P577

2011-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51821816

http://www.w3.org/2001/XMLSchema#string

P698

22108196

http://www.w3.org/2001/XMLSchema#string

P921

P932

3488768

http://www.w3.org/2001/XMLSchema#string